OPTIONS OF CORRECTING INSULIN RESISTANCE AND PROINFLAMMATORY CYTOKINE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Authors

DOI:

https://doi.org/10.21856/j-PEP.2022.1.05

Keywords:

type 2 diabetes mellitus, interleukin-6, C-reactive protein, empagliflozin

Abstract

The objective of this study was to investigate the effect of empagliflozin on insulin resistance, leptin and proinflammatory cytokine levels in patients with type 2 diabetes.

Materials and methods. 100 patients with type 2 diabetes with normal weight, overweight and obesity of various degrees were examined. Anthropometric indicators were taken. Levels of leptin, IL-6, CRP in blood serum were determined, HOMA index was calculated.

Results. Insulin resistance in all groups of patients was associated with abdominal obesity, hyperleptinemia (r = 0.505, p < 0.05), (r = 0.846, p < 0.05), (r = 0.886, p < 0.05), (r = 0.736, p < 0.05) in patients from Group I-IV. Patients of all examined groups have shown a significant increase in IL-6 levels, compared with the control group (p < 0.05), but the level of IL-6 in patients from Group II, III and IV have been significantly higher than those from Group I (p < 0.05) and the control group (p < 0.05) and has increased along with the weight gain. Similarly, the highest indices of CRP levels have been found in patients from Group IV which proves a high pro-inflammatory activity in these patients with type 2 diabetes and obesity. After a 6-month course of treatment patients taking empagliflozin, regardless of BMI, have shown significantly decreased levels of both IL-6 (p < 0.05), and CRP (p < 0.05). Levels of leptin (p < 0.05) and HOMA index (p < 0.05) were significantly reduced in obese patients, too.

Conclusions. As a result of the study, it has been established that the use of empagliflozin in the dose of 10 mg per day for 6 months has had a significant effect on anthropometric parameters and markers of insulin resistance (HOMA index, leptin) in patients with type 2 diabetes and obesity. A significant decrease in the levels of IL-6 and CRP under the influence of empagliflozin, regardless of the patient’s weight has been revealed.

References

Townsend N, Wilson L, Bhatnagar P, et al. Eur Heart J 2016;37(42): 3232-3245.

Katsiki N, Mikhailidis DP, Banach M. Acta Pharmacologica Sinica 2018;39(7): 1176-1188. https://doi.org/10.1038/aps.2018.40.

Pérez-Pérez A, et al. Cytokine Growth Factor Rev 2017;35: 71-84.

Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH. Clin Ther 2016;38(6): 1288-1298. https://doi.org/10.1016/j.clinthera.2016.04.037.

Choi KM, Lee J, et al. Diabetes Res Clin Pract 2004;64: 99-106.

Niskanen L, Laaksonen DE, Nyyssönen K, et al. Hypertension 2004;44: 859-865. https://doi.org/10.1161/01.HYP.0000146691.51307.84.

Mechanick JI, Zhao S, Garvey WT. Glob Heart 2018;13(2): 113-127. https://doi.org/10.1016/j.gheart.2017.10.003.

Didushko OM, Kobrynska OY, et al. Prensa Med Argent 2020;2: 003.

Rodrigues KF, Pietrani NT, Bosco AA, et al. Arch Endocrinol Metab 2017;61(5): 438-446. https://doi.org/10.1590/2359-3997000000254.

Tangvarasittichai S, Pongthaisong S, Tangvarasittichai O. Indian J Clin Biochem 2016;31(1): 68-74. https://doi.org/10.1007/s12291-015-0514-0.

Kravchun NO, Alkhamid MKh, Misiura KV, et al. Probl Endocrine Pathol 2021;75(1): 34-42. https://doi.org/10.21856/j-PEP.2021.1.05.

Katsiki N, Mikhailidis DP, Banach M. Acta Pharmacol Sin 2018;39(7): 1176-1188. https://doi.org/10.1038/aps.2018.40.

Park SH, et al. Cardiovasc Diabetol 2020;19: 19. https://doi.org/10.1186/s12933-020-00997-7.

Hattori S. Diabetol Metab Syndr 2018;10: 93. https://doi.org/10.1186/s13098-018-0395-5.

Vallon V, Verma S. Ann Rev Physiol 2021;83(1): 503-528. https://doi.org/10.1146/annurev-physiol-031620-095920.

Downloads

Published

2022-03-15

How to Cite

Kobrynska, O., & Didushko, O. (2022). OPTIONS OF CORRECTING INSULIN RESISTANCE AND PROINFLAMMATORY CYTOKINE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Problems of Endocrine Pathology, 79(1), 36-42. https://doi.org/10.21856/j-PEP.2022.1.05

Issue

Section

CLINICAL ENDOCRINOLOGY